Levaquin Lawsuit Update: Antibiotic Peripheral Neuropathy Claims Near 200 in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports

September 17, 2015 (PRLEAP.COM) Business News
September 17, 2015 - The federal multidistrict litigation created for Levaquin lawsuits (http://www.levaquinlawsuitcenter.com/) and other fluoroquinolone antibiotic cases involving the medications' alleged association with peripheral neuropathy has grown significantly since its establishment just one month ago. According to an updated Docket Report issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on September 15th, at least 192 claims have been filed in the proceeding on behalf of plaintiffs who were allegedly harmed by Levaquin, Cipro and Avelox. The JPML's August 17th Transfer Order establishing the centralized litigation initially sent 78 cases to the U.S. District Court, District of Minnesota, indicating that 114 new claims have since been added to the proceeding. (In Re: Fluoroquinolone Products Liability Litigation MDL No. 2642)

"Our Firm has heard from numerous individuals who claim to have experienced serious and permanent nerve damage related to the use of fluoroquinolone antibiotics. Millions of people have been treated with these medications, so it is not surprising that this litigation is growing at a fairly rapid pace," says Sandy A. Liebhard LLP, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently evaluating product liability lawsuits on behalf of individuals who allegedly developed peripheral neuropathy due to Levaquin, Avelox or Cipro.

Fluoroquinolone Litigation
Levaquin and other fluoroquinolone antibiotics are approved to treat certain bacterial infections, including pneumonia, urinary tract infections, E. coli, salmonella, and staph infections. According to the U.S. Food & Drug Administration (FDA), more than 23 million people received a prescription for oral fluoroquinolones in 2011. Court records indicate that the litigation involving fluoroquinolone antibiotics and peripheral neuropathy began to grow in 2013, shortly after the FDA ordered the drugs' manufacturers to strengthen wording on their labels regarding the potential for the condition. Plaintiffs claim that had previous warnings been adequate, many patients could have avoided this serious and debilitating complication.

Patients who were diagnosed with permanent peripheral neuropathy that may be related to the use of Levaquin, Cipro or Avelox could be eligible to join this growing litigation. To learn more, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can also be obtained by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP

Share Article